Survival Analysis of Stage Ⅳ Metastatic Gastric Cancer Patients Treated with HangAm-Plus

Objective:To evaluate the efficacy of HangAm-Plus(HAP)on stageⅣmetastatic gastric cancer by analyzing the treated patients’overall survival outcome.Methods:Following the study eligibility,overall survival and one year survival rate of 44 stageⅣmetastatic gastric cancer patients who visited EastWest Cancer Center(EWCC)were analyzed.The study consisted of two arms:HAP treatment only(n=18)and combined treatment of concurrent conventional chemotherapy and HAP(n=26).Patient characteristics by gender,age,surgical intervention,Eastern Cooperative Oncology Group(ECOG)score,treatment duration(<4 weeks or≥4 weeks),and lines of the chemotherapy received were assessed.Treatment related side effects were also assessed.Results:The median survival of combined group was longer(10.0 months)than that of HAP group(5.1 months).One-year survival rate of combined treatment group and HAP group was 38.5%±9.5%and 33.3%±11.1%,respectively(P>0.05).One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7%and 8.3%±8.0%,respectively(P=0.001).Conclusions:The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stageⅣmetastatic gastric cancer treated with conventional chemotherapy.Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.